Nyxoah
The Path to Restful Nights
The Path to Restful Nights
Nyxoah is a pioneering medical device company developing a breakthrough therapeutic solution for the treatment of Obstructive Sleep Apnea (OSA). Our mission is to become a world leading company by offering unique patient-centric neuromodulation solutions, developed by passionate and exceptionally driven people Nyxoah's therapy Genio® offers: - Unparalleled clinical efficacy - Increased patient comfort, therapy compliance and quality of life - Minimally invasive approach, thus streamlining patient flow and reducing surgery related risks - Positive health economics outcomes by reducing the burden of OSA and its comorbidities
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | €37.50M | 1 | European Investment Bank | 03 Jul 2024 |
| Post-IPO Equity | $50.00M | - | 23 May 2024 | |
| Post-IPO Equity | $3.00M | - | 27 Mar 2023 | |
| Post-IPO Equity | €13.35M | - | 23 Mar 2023 | |
| Corporate Round | €25.00M | 2 |
|
12 Feb 2020 |
No recent news or press coverage available for Nyxoah.
We care about your data, and we'd love to use cookies make your experience better.
